ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1378

Understanding Diagnostic Pathways in Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Shervin Assassi1, Nan Shao2, Ziwei Yin2, Elizabeth Volkmann3, Donald Zoz2 and Thomas Leonard2, 1University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, 2Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, 3University of California, Los Angeles, Los Angeles, CA

Meeting: ACR Convergence 2020

Keywords: pulmonary, Scleroderma

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of SSc. SSc-ILD is usually detected in a patient known to have SSc, but ILD may be the initial presentation of SSc. Optum is a health insurance database covering >60 million patients, which is representative of the commercially insured population in the US. We used data from the Optum database to investigate the documentation of ILD prior to a diagnosis of SSc.

Methods: The study period was between 1 January 2007 and 30 June 2019. The “ICD-9 cohort” comprised patients aged ≥18 years, with an SSc index date (date of first insurance claim related to SSc) between 1 January 2010 and 30 September 2015 based on ICD-9-CM codes, ≥2 medical claims associated with SSc on different dates within a 1-year period, and ≥3 years of continuous enrollment in the database prior to the SSc index date. The “ICD-10 cohort” comprised patients aged ≥18 years, with an SSc index date between 1 October 2017 and 30 June 2019 based on ICD-10-CM codes, ≥2 medical claims associated with SSc on different dates within a 1-year period, and ≥2 years of continuous enrollment in the database prior to the SSc index date. ILD was defined as ≥2 medical claims associated with ILD on different dates. We identified patients who had their second claim associated with ILD prior to their SSc index date in the two cohorts. Analyses were descriptive.

Results: The ICD-9 and ICD-10 cohorts consisted of 1779 and 1032 patients with SSc, respectively. In these two cohorts, 7.6% and 9.3% of patients respectively, had their second claim associated with ILD prior to their SSc index date (Table). The second ILD claim occurred >1 year prior to the SSc index date in 4.3% of patients in the ICD-9 cohort and 5.6% of patients in the ICD-10 cohort.

Conclusion: Based on data from a large US health insurance database, 4–6% of patients with SSc had claims for ILD more than 1 year prior to a claim for SSc. These data are consistent with previous studies showing that SSc can have an impact on the lung early in the course of SSc and demonstrate the importance of screening patients with ILD for SSc.


Disclosure: S. Assassi, Momenta, 1, corbus, 1, Integrity Continuing Education, 1, Boehringer Ingelheim, 1, 2, 3; N. Shao, Boehringer Ingelheim Pharmaceuticals, 3; Z. Yin, Boehringer Ingelheim Pharmaceuticals, 3; E. Volkmann, Boehringer Ingelheim, 2, 5, Forbius, 2, 5, Corbus, 2; D. Zoz, Boehringer Ingelheim Pharmaceuticals, 3; T. Leonard, Boehringer Ingelheim Pharmaceuticals, 3.

To cite this abstract in AMA style:

Assassi S, Shao N, Yin Z, Volkmann E, Zoz D, Leonard T. Understanding Diagnostic Pathways in Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/understanding-diagnostic-pathways-in-systemic-sclerosis-and-systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/understanding-diagnostic-pathways-in-systemic-sclerosis-and-systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology